Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T14:17:15.076Z.
Calculation as of: 2026-10-06T14:17:15.076Z.
Quote observation: 2026-10-06T14:15:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
EARNINGS YIELD
N/A
Market Cap
$1.32B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Earnings Yield
N/A
TTM Avg
818.17%
3Y Avg
818.17%
5Y Avg
818.17%
Market Cap
$1.46B
Earnings Yield
8.05%
TTM Avg
4.29%
3Y Avg
4.28%
5Y Avg
3.97%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.35B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | 818.17% | 818.17% | 818.17% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 11.20% | 10.64% | 10.64% | 2.45% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.05% | 4.29% | 4.28% | 3.97% |
| Kardigan, Inc. (KARD)vs › | $1.18B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
